An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals

British Journal of Dermatology

Volumn 168, Issue 2, 2013, Pages 374-380

  Mrowietz, Ulrich ^a   Kragballe, K ^b   Reich, K ^c   Griffiths, C E M ^d   Gu, Y ^e   Wang, Y ^e   Rozzo, S J ^e  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c DERMATOLOGIKUM HAMBURG   (Germany)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; PLACEBO;

ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SHORT FORM 36; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE III AS TOPIC; CONSENSUS; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; GOALS; HUMANS; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84873192382     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11214.x     Document Type: Article

References (22)

1. Farber EM, Nall L,. Epidemiology: natural history and genetics. In: Psoriasis (, Roenigk HH, Maibach HI, eds), 3rd edn. New York: Marcel Dekker Inc, 1998; 107-58.
2. Nestle FO, Kaplan DH, Barker JN,. Psoriasis. N Engl J Med 2009; 361: 496-509.
3. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2010; 23 (Suppl. 2): 1-70.
4. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
5. Augustin M, Krüger K, Radtke MA, et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multi-center cross-sectional study in Germany. Dermatology 2008; 216: 366-72.
6. Nast A, Erdmann R, Hofelich V, et al. Do guidelines change the way we treat? Studying prescription behaviour among private practitioners before and after the publication of the German Psoriasis Guidelines. Arch Dermatol Res 2009; 301: 553-9.
7. Richards HL, Fortune DG, O'Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41: 581-3.
8. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-9.
9. Nast A, Reytan N, Rosumeck S, et al. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. J Eur Acad Dermatol Venereol 2008; 22: 1337-42.
10. American Academy of Dermatology Work Group, Menter A, Korman NJ, et al. Guidelines for care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011; 65: 137-74.
11. Smith CH, Anstey AV, Barker NJWN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
12. Nast A, Rzany B,. Three years after the publication of the German (S3) evidence based psoriasis guidelines-was it worth the effort? J Dtsch Dermatol Ges 2009; 7: 1044-7.
13. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66.
14. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
15. Thaçi D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 2010; 163: 402-11.
16. Reich K, Langley RG, Papp KA, et al. 52-week trial of briakinumab vs. methotrexate in psoriasis. N Engl J Med 2011; 365: 1586-96.
17. Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165: 1109-17.
18. Horn EJ, Fox KM, Patel V, et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 2007; 57: 957-62.
19. Augustin M, Holland B, Dartsch D, et al. Adherence in the treatment of psoriasis: a systematic review. Dermatology 2011; 222: 363-74.
20. Poulin Y, Papp KA, Wasel NR, et al. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. Int J Dermatol 2010; 49: 1368-75.
21. Chan SA, Hussain F, Lawson LG, Ormerod AD,. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J Dermatolog Treat 2011 Sep 7 [Epub ahead of print].
22. Schäfer I, Hacker J, Rustenbach SJ, et al. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol 2010; 20: 62-7.